Glucocorticoids are growth-inhibiting steroids. They have been reported to reduce muscle growth by reducing protein synthesis. However, their actions on muscle protein degradation remain equivocal. Glucocorticoids have been reported to transiently increase muscle protein degradation, to not affect this process and to reduce muscle protein degradation. Reasons for these conflicting reports are not understood but may be related to species, glucocorticoid doses and route and duration of administration. Dexamethasone is a synthetic glucocorticoid and is not rapidly metabolized in vivo. As an inflammatory agent, dexamethasone is more potent than natural glucocorticoids. The objective of this study was to clarify the role in molecular regulation of calpain expression as a proteolytic catalyst linked to initiation of myofibrillar protein degradation by using glucocorticoid-dependent changes in muscle protein degradation as a model. A secondary objective of investigating molecular mechanisms responsible for regulation of calpain expression was conducted by examining effects of a synthetic glucocorticoid --dexamethasone on calpains and calpastatin activities and steady-state mRNA concentrations encoding these proteins. Female New Zealand White rabbits (1.8-2.1 kg) were treated with 1 mg dexamethasone/kg BW/day for 0 day, 1 day, 2 days or 4 days by daily subcutaneous injection. Cranial biceps femoris were taken for analysis of muscle protein concentration, muscle RNA concentration, ribosomal capacity, N'-methylhistidine (NMH) concentration and calpains and calpastatin activities. Because glucocorticoids may mediate their actions indirectly via other hormones, temporal effects of dexamethasone on plasma T3 and T4 concentrations were also examined. Dexamethasone transiently decreased (P < .05) final body weight and total body weight gain in the 1-day dexamethasone-treated rabbits, but food intake was maintained in both control and dexamethasone-treated rabbits (P > .05). Muscle protein concentration was unaffected (P > . 05) by dexamethasone, while dexamethasone decreased (P < .05) muscle RNA concentration in the 4-day dexamethasone-treated rabbits and tended to decrease ribosomal capacity (P > . 05) gradually as duration of dexamethasone treatment increased. Although urinary NMH excretion, which serves as an index of myofibrillar protein degradation, was not affected by dexamethasone (P > .05), the ratio of urinary NMH excretion to urinary creatinine output was reduced significantly (P < .05) by 4 days of dexamethasone treatment compared to 1 day of dexamethasone treatment. Also, muscle NMH concentration was reduced (P < .05) by dexamethasone treatment. These data indicate that dexamethasone treatment may have reduced muscle protein degradation. Calpain I, calpain II and calpastatin activities were not affected by dexamethasone (P > . 05) although both calpain I and calpain II activities tended to decrease and calpastatin activity had a tendency to increase as duration of dexamethasone treatment increased. Maximum effects of dexamethasone on both calpains, urinary NMH excretion and muscle NMH concentration were detected following 2 days of administration. These results indicated that the temporal decrease in rabbit skeletal muscle protein degradation by dexamethasone was related to calpains and calpastatin. mRNA concentrations encoding calpain I increased (P < .05) in the 1-day dexamethasone-treated rabbits, while mRNA concentrations encoding calpain II decreased (P < .05). These results imply that dexamethasone can affect calpain I and calpain II gene expression in an opposing manner (up-regulation and down-regulation). Plasma T₃ concentration but not plasma T₄ concentration was significantly reduced (P < . 05) by dexamethasone treatment. Because T₃ stimulates myofibrillar protein degradation, its lower concentration in dexamethasone-treated rabbits may account for the apparent reduction in protein degradation caused by dexamethasone. In this study, the observed effects of dexamethasone on muscle protein degradation may be the combination of direct and indirect responses. Thus, in vitro studies will be needed in order to clarify the direct effects of dexamethasone on muscle protein degradation. / Graduation date: 1991

Tesis de grado, Universidad Mayor de San Andres, Facultad de Agronomia, Carrera de Ingenieria Agronomica. / Abstract in Spanish and English.

No description available.

No description available.

Thesis (Ph. D.)--University of Adelaide, 1967. / Includes bibliographical references (p. 131-140).

Thesis--University of Adelaide, Dept. of Zoology, 1962. / Typewritten.

Thesis (M.S.)--University of Wisconsin--Madison, 1962. / Typescript. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (M.S.)--University of Wisconsin--Madison, 1970. / eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (Ph. D.)--University of Wisconsin--Madison, 1924. / Reprinted from The American journal of anatomy, Vol. 37, No. 3, July, 1926. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (p. 496-497).

Thesis (M.S.)--University of Wisconsin--Madison, 1965. / eContent provider-neutral record in process. Description based on print version record. Bibliography: l. 51-58.